CAMZYOS® Study Designs for EXPLORER-HCM and EXPLORER-LTE

Explore this page:    |    EXPLORER-HCM    |    EXPLORER-‍LTE

EXPLORER-HCM: Study Design

EXPLORER-HCM: A Groundbreaking Phase 3 Trial for Patients with NYHA Class II–III Obstructive HCM1

A randomized, double-blind, placebo-controlled, 30-week trial that evaluated the efficacy and safety of CAMZYOS vs placebo1

The efficacy and safety of CAMZYOS were evaluated in EXPLORER-HCM, a phase 3 trial that enrolled 251 adult patients.1

Select Inclusion Criteria1

  • Symptomatic NYHA Class II-III obstructive HCM 
  • LVOT peak gradient ≥50 mmHg and LVEF ≥55% 

Select Exclusion Criteria1,2

  • Underwent SRT within 6 months prior to screening, or planned during study
  • Treatment (within 14 days of screening) or planned treatment with disopyramide, ranolazine, or a combination of BBs and CCBs 

Treatment2

  • In the active treatment arm: 5 mg of CAMZYOS with opportunities for dose titration at Weeks 8 and 14 (based on patient response with Valsalva LVOT gradient and LVEF) 
  • During the treatment period, patients were evaluated every 2 to 4 weeks 

Majority of patients (92%) were on background therapy with a BB or CCB CAMZYOS (n=119/123) | Placebo (n=112/128)2 

See select baseline patient characteristics below >

The primary composite functional endpoint used 2 component parameters to assess exercise capacity and impact on patients’ symptoms1

Exercise capacity was assessed with pVO2, an objective measure of peak oxygen consumption during CPET3* 

Symptoms were assessed with NYHA class, a subjective measure of symptom burden3 

The proportion of patients who achieved either of the following changes from baseline to Week 301:

≥1.5 mL/kg/min improvement in pVO2
AND
≥1 NYHA class improvement

—OR—

≥3.0 mL/kg/min improvement in pVO2
AND
No worsening in NYHA class

Secondary endpoints (from baseline to Week 30)1,2

  • Change in postexercise LVOT peak gradient
  • Change in pVO2
  • Proportion of patients with ≥1 NYHA class improvement
  • Change in KCCQ-23–CSS
  • Change in HCMSQ-SoB

All assessments for secondary endpoints were performed and Type 1 error was controlled in hierarchical order (sequence as indicated above) upon achieving significance in the primary endpoint (with two-tailed P<0.05 required to proceed). Data based on all randomized patients who received ≥1 dose of study treatment. Model-estimated least-square mean differences were reported for continuous variable. Missing NYHA class data at Week 30 were imputed with the Week 26 value in the case of NYHA response. Patients with a nonevaluable primary endpoint and NYHA secondary endpoint were considered as nonresponders. LVOT gradient, pVO2, KCCQ-23—CSS, and HCMSQ-SoB were analyzed with all available gradient (pVO2) or mixed-effect model for repeated measurements (KCCQ-23–CSS, HCMSQ-SoB).2

* Type of exercise testing used in EXPLORER-HCM included either a treadmill or a bicycle.3

BB=beta blocker; CCB=calcium channel blocker; CI=confidence interval; CPET=Cardiopulmonary Exercise Testing; HCM=hypertrophic cardiomyopathy; HCMSQ-SoB=Hypertrophic Cardiomyopathy Symptom Questionnaire Shortness of Breath; KCCQ-23–CSS=Kansas City Cardiomyopathy Questionnaire-23–Clinical Summary Score; LTE=long-term extension; LVEF=left ventricular ejection fraction; LVOT=left ventricular outflow tract; NYHA=New York Heart; Association; SRT=septal reduction therapy.

Select baseline patient characteristics in EXPLORER-HCM1,2

Select baseline patient characteristics
Values in the table are mean ± SD, n (%) CAMZYOS (n=123) Placebo (n=128)
Age, mean (SD), years 59 (12.2) 59 (11.8)
Women, n (%) 57 (46) 45 (35)
Race, n (%)
White 115 (94) 114 (89)
Black or African American 1 (1) 5 (4)
American Indian or Alaska Native 0 1 (1)
Asian 4 (3) 2 (2)
Unknown 3 (2) 6 (5)
Background HCM treatment, n (%)
Beta blocker
Calcium channel blocker†		 94 (76)
25 (20)		 95 (74)
17 (13)
NYHA class, n (%)
Class II
Class III		 88 (72)
35 (28)		 95 (74)
33 (26)
pVO2 mean (SD), mL/kg/min 18.9 (4.9) 19.9 (4.9)
LVOT gradient at baseline, mean (SD), mmHg
Valsalva
Postexercise‡		 72 (32)
86 (34)		 74 (32)
84 (36)
LVEF, mean (SD), (%) 74 (6) 74 (6)
Critical cardiac history
Atrial fibrillation, n (%) 12 (10) 23 (18)
Implantable cardioverter-‌defibrillator, n (%) 27 (22) 29 (23)
Prior invasive SRT, n (%) 11 (9) 8 (6)
† Nondihydropyridine calcium channel blockers.2
‡ Data missing for one patient in the CAMZYOS group and one patient in the placebo group.2

SD=standard deviation.

Study procedures used in EXPLORER-HCM to determine the efficacy and safety of CAMZYOS

EXPLORER-LTE: Study Design

EXPLORER-LTE: Interim Readout at ~3.5 Years from a 5-Year, Long-Term Extension Trial4

  • EXPLORER-LTE is one of two cohorts from MAVA-LTE: a single-arm, open-label, ongoing extension of the phase 3 EXPLORER-HCM study to evaluate the long-term safety and efficacy of CAMZYOS4
  • 231 of 251 patients from the pivotal trial enrolled in the long-term extension after an 8-week washout period4

The EXPLORER-LTE cohort of the MAVA-LTE trial sought to evaluate the long-term safety and efficacy of CAMZYOS starting at 5 mg in eligible adults who completed the EXPLORER-HCM trial. The EXPLORER-LTE cohort (n=231) is a single-arm without an active comparator.1,4

EXPLORER-LTE objectives evaluated the long-term effect of CAMZYOS on5:

Inspect

  • Primary objective: safety and tolerability

  • Secondary objectives: changes in NYHA class, LVOT gradients at rest and with Valsalva, and LVEF 

  • Exploratory objectives: changes in NT-proBNP and measures of left ventricle filling

STUDY LIMITATIONS

  • These data are not included in the CAMZYOS US Full Prescribing Information. Caution should be used in interpreting the data as the data were not statistically tested for significance, but are only descriptive in nature
  • There are limitations with the data, including decreased sample size and different continuation rates based on the continued involvement of responders and attrition of nonresponders
  • MAVA-LTE, including the EXPLORER-LTE cohort, is a single-arm study without an active comparator; patients in EXPLORER-LTE were part of either the CAMZYOS or placebo group in EXPLORER-HCM; therefore, baseline characteristics for EXPLORER-LTE changed due to time and consolidation of both arms to one cohort
  • The EXPLORER-LTE cohort of MAVA-LTE included 14 patients who were NYHA Class I at screening. These patients were included in the EXPLORER-HCM trial; 5 had received CAMZYOS, and 9 were in the placebo group

Study design for EXPLORER-LTE cohort4,6

EXPLORER-LTE 5-Year Study Design EXPLORER-LTE 5-Year Study Design

Swipe left for full chart

§ This is not consistent with the current approved dosing schedule per the US Full Prescribing Information.8

EOS=end of study; EOT=end of treatment; NT-proBNP=N-terminal pro b-type natriuretic peptide; QD=once daily. 

Select Patient Baseline Characteristics for EXPLORER-LTE4

Characteristic EXPLORER-LTE 
cohort (n=123)
Age, mean (SD), years 60.0 (11.9)
Female, n (%) 91 (39.4)
Background HCM treatment, n (%)
  • BBs
  • CCBs
176 (76.2)
38 (16.5)
NYHA class, n (%)
  • Class I
  • Class II
  • Class III
14 (6.1)
152 (65.8)
65 (28.1)
NT-proBNP, median (IQR), ng/L 766.0 (323.0, 1593.0)
[n=230]
LVOT gradient at baseline, mean (SD), mmHg
  • Resting
  • Valsalva
48.3 (31.9)
69.5 (33.3) [n=228]
LVEF, mean (SD), % 74.0 (5.9) [n=230]
Time on study, median (range), weeks 166.1 (6.0–228.1)

Baseline is defined as last non-missing measurement before the first dose of CAMZYOS in MAVA-LTE.4
IQR=interquartile range.

References:

  1. CAMZYOS [package insert]. Princeton, NJ: Bristol-Myers Squibb Company; 2025.
  2. Olivotto I, Oreziak A, Barriales-Villa R, et al; EXPLORER-HCM study investigators. Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2020;396(10253):759-769. doi:10.1016/S0140-6736(20)31792-X
  3. Ho CY, Day SM, Ashley EA, et al; SHaRe Investigators Genotype and lifetime burden of disease in hypertrophic cardiomyopathy: insights from the Sarcomeric Human Cardiomyopathy Registry (SHaRe). Circulation. 2018;138(14):1387-1398. doi:10.1161/CIRCULATIONAHA.117.033200
  4. Garcia-Pavia P, Oręziak A, Masri A, et al. Long-term effect of mavacamten in obstructive hypertrophic cardiomyopathy. Eur Heart J. 2024;45(47):5071-5083. doi:10.1093/eurheartj/ehae579
  5. Rader F, Oręziak A, Choudhury L, et al. Mavacamten treatment for symptomatic obstructive hypertrophic cardiomyopathy: interim results from the MAVA-LTE study, EXPLORER-LTE cohort. JACC Heart Fail. 2024;12(1):164-177. doi:10.1016/j.jchf.2023.09.028
  6. Garcia-Pavia P, Oręziak A, Masri A, et al. Long-term effects of mavacamten treatment in obstructive hypertrophic cardiomyopathy (HCM): updated cumulative analysis of the EXPLORER cohort of MAVA-long-term extension (LTE) study up to 120 weeks. Presented at: ESC 2023. Oral presentation 835382. 
  7. Garcia-Pavia P, Oręziak A, Masri A, et al. Long-term effect of mavacamten in obstructive hypertrophic cardiomyopathy. Eur Heart J. 2024 [supplementary appendix]. doi:10.1093/eurheartj/ehae579
  8. Argulian E, Sherrid MV, Messerli FH. Misconceptions and facts about hypertrophic cardiomyopathy.  Am J Med. 2016;129(2):148-152. doi:10.1016/j.amjmed.2015.07.035

3500-US-2500554 09/25

IMPORTANT SAFETY INFORMATION

WARNING: RISK OF HEART FAILURE

CAMZYOS reduces left ventricular ejection fraction (LVEF) and can cause heart failure due to systolic dysfunction.

Echocardiogram assessments of LVEF are required prior to and during treatment with CAMZYOS. Initiation of CAMZYOS in patients with LVEF <55% is not recommended. Interrupt CAMZYOS if LVEF is <50% at any visit or if the patient experiences heart failure symptoms or worsening clinical status.

Concomitant use of CAMZYOS with certain cytochrome P450 inhibitors or discontinuation of certain cytochrome P450 inducers may increase the risk of heart failure due to systolic dysfunction; therefore, the use of CAMZYOS is contraindicated with the following:

 
  • Strong CYP2C19 inhibitors
  • Moderate to strong CYP2C19 inducers or moderate to strong CYP3A4 inducers

Because of the risk of heart failure due to systolic dysfunction, CAMZYOS is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called the CAMZYOS REMS PROGRAM.

CONTRAINDICATIONS

CAMZYOS is contraindicated with concomitant use of:

 
  • Strong CYP2C19 inhibitors
  • Moderate to strong CYP2C19 inducers or moderate to strong CYP3A4 inducers

WARNINGS AND PRECAUTIONS

Heart Failure
CAMZYOS reduces systolic contraction and can cause heart failure or significantly reduce ventricular function. Patients who experience a serious intercurrent illness (eg, serious infection) or arrhythmia (eg, atrial fibrillation or other uncontrolled tachyarrhythmia) are at greater risk of developing systolic dysfunction and heart failure.

Assess the patient’s clinical status and LVEF prior to and regularly during treatment and adjust the CAMZYOS dose accordingly. New or worsening arrhythmia, dyspnea, chest pain, fatigue, palpitations, leg edema, or elevations in N-terminal pro-B-type natriuretic peptide  (NT-proBNP)  may be signs and symptoms of heart failure and should also prompt an evaluation of cardiac function.

Asymptomatic LVEF reduction, intercurrent illnesses, and arrhythmias require additional dosing considerations.

Initiation of CAMZYOS in patients with LVEF <55% is not recommended. Avoid concomitant use of CAMZYOS in patients on disopyramide, ranolazine, verapamil with a beta blocker, or diltiazem with a beta blocker as these medications and combinations increase the risk of left ventricular systolic dysfunction and heart failure symptoms and clinical experience is limited.

CYP450 Drug Interactions Leading to Heart Failure or Loss of Effectiveness

CAMZYOS is primarily metabolized by CYP2C19 and CYP3A4 enzymes. Concomitant use of CAMZYOS and drugs that interact with these enzymes may lead to life-threatening drug interactions such as heart failure or loss of effectiveness.

Advise patients of the potential for drug interactions, including with over-the-counter medications (such as omeprazole, esomeprazole, or cimetidine). Advise patients to inform their healthcare provider of all concomitant products prior to and during CAMZYOS treatment.

CAMZYOS Risk Evaluation and Mitigation Strategy (REMS) Program

CAMZYOS is only available through a restricted program called the CAMZYOS REMS Program because of the risk of heart failure due to systolic dysfunction. Notable requirements of the CAMZYOS REMS Program include the following:

 
  • Prescribers must be certified by enrolling in the REMS Program
  • Patients must enroll in the REMS Program and comply with ongoing monitoring requirements
  • Pharmacies must be certified by enrolling in the REMS Program and must only dispense to patients who are authorized to receive CAMZYOS
  • Wholesalers and distributors must only distribute to certified pharmacies

Further information is available at  www.CAMZYOSREMS.com  or by telephone at  1-833-628-7367.

Embryo-Fetal Toxicity

CAMZYOS may cause fetal toxicity when administered to a pregnant female, based on animal studies. Confirm absence of pregnancy in females of reproductive potential prior to treatment and advise patients to use effective contraception during treatment with CAMZYOS and for 4 months after the last dose. Combined hormonal contraceptives (CHCs) containing a combination of ethinyl estradiol and norethindrone may be used with CAMZYOS. However, CAMZYOS may reduce the effectiveness of certain other CHCs. If these CHCs are used, advise patients to add nonhormonal contraception (such as condoms) during concomitant use and for 4 months after the last dose of CAMZYOS.

ADVERSE REACTIONS

In the EXPLORER-HCM trial, adverse reactions occurring in >5% of patients and more commonly in the CAMZYOS group than in the placebo group were dizziness (27% vs 18%) and syncope (6% vs 2%). There were no new adverse reactions identified in VALOR-HCM.

Effects on Systolic Function

In the EXPLORER-HCM trial, mean (SD) resting LVEF was 74% (6) at baseline in both treatment groups. Mean (SD) absolute change from baseline in LVEF was -4% (8) in the CAMZYOS group and 0% (7) in the placebo group over the 30-week treatment period. At Week 38, following an 8-week interruption of trial drug, mean LVEF was similar to baseline for both treatment groups. In the EXPLORER-HCM trial, 7 (6%) patients in the CAMZYOS group and 2 (2%) patients in the placebo group experienced reversible reductions in LVEF <50% (median 48%: range 35-49%) while on treatment. In all 7 patients treated with CAMZYOS, LVEF recovered following interruption of CAMZYOS.

DRUG INTERACTIONS

Potential for Other Drugs to Affect Plasma Concentrations of CAMZYOS

CAMZYOS is primarily metabolized by CYP2C19 and to a lesser extent by CYP3A4 and CYP2C9. Inducers and inhibitors of CYP2C19 and moderate to strong inhibitors or inducers of CYP3A4 may affect the exposures of CAMZYOS.

Impact of Other Drugs on CAMZYOS:

 
  • Strong CYP2C19 Inhibitors: Concomitant use increases CAMZYOS exposure, which may increase the risk of heart failure due to systolic dysfunction. Concomitant use is contraindicated
  • Moderate to Strong CYP2C19 Inducers or Moderate to Strong CYP3A4 Inducers:  Concomitant use decreases CAMZYOS exposure, which may reduce CAMZYOS’ efficacy. The risk of heart failure due to systolic dysfunction may increase with discontinuation of these inducers as the levels of induced enzyme normalizes. Concomitant use is contraindicated
  • Weak CYP2C19 Inhibitors or Moderate CYP3A4 Inhibitors: Concomitant use with a weak CYP2C19 inhibitor or a moderate CYP3A4 inhibitor increases CAMZYOS exposure, which may increase the risk of adverse drug reactions. Initiate CAMZYOS at the recommended starting dose of 5 mg orally once daily in patients who are on stable therapy with a weak CYP2C19 inhibitor or a moderate CYP3A4 inhibitor. Reduce dose of CAMZYOS by one level (ie, 15 to 10 mg, 10 to 5 mg, or 5 to 2.5 mg) in patients who are on CAMZYOS treatment and intend to initiate a weak CYP2C19 inhibitor or a moderate CYP3A4 inhibitor. Schedule clinical and echocardiographic assessment 4 weeks after inhibitor initiation, and do not up-titrate CAMZYOS until 12 weeks after inhibitor initiation. Avoid initiation of concomitant weak CYP2C19 and moderate CYP3A4 inhibitors in patients who are on stable treatment with 2.5 mg of CAMZYOS because a lower dose is not available. For short-term use (eg 1 week), interrupt CAMZYOS for the duration of treatment with a weak inhibitor of CYP2C19 or a moderate inhibitor of CYP3A4. CAMZYOS may be reinitiated at the previous dose immediately on discontinuation of concomitant therapy
  • Moderate CYP2C19 Inhibitors or Strong CYP3A4 Inhibitors: Concomitant use with a moderate CYP2C19 inhibitor or strong CYP3A4 inhibitor increases CAMZYOS exposure, which may increase the risk of adverse drug reactions. Discontinuing use of a moderate CYP2C19 inhibitor or strong CYP3A4 inhibitor after long-term concomitant use may decrease CAMZYOS exposure, which may reduce CAMZYOS’ efficacy. Initiate CAMZYOS at a starting dosage of 2.5 mg orally once daily in patients who are on a stable therapy with a moderate CYP2C19 inhibitor or a strong CYP3A4 inhibitor. Reduce dose of CAMZYOS by one level (ie, 15 to 10 mg, 10 to 5 mg, or 5 to 2.5 mg) in patients who are on CAMZYOS and intend to initiate a moderate CYP2C19 inhibitor or a strong CYP3A4 inhibitor. Avoid initiation of concomitant moderate CYP2C19 and strong CYP3A4 inhibitors in patients who are on a stable treatment with 2.5 mg of CAMZYOS because a lower dose is not available. An increase in dose of CAMZYOS may be needed if the moderate inhibitor of CYP2C19 or strong inhibitor of CYP3A4 is discontinued after long-term concomitant use. Monitor for new or worsening symptoms. For short-term use (ie, when CAMZYOS dose modification is not feasible), interrupt CAMZYOS for the duration of treatment with a moderate inhibitor of CYP2C19 or a strong inhibitor of CYP3A4. CAMZYOS may be reinitiated at the previous dose immediately on discontinuation of concomitant therapy

Potential for CAMZYOS to Affect Plasma Concentrations of Other Drugs

CAMZYOS is an inducer of CYP3A4, CYP2C9, and CYP2C19. Concomitant use with CYP3A4, CYP2C9, or CYP2C19 substrates may reduce plasma concentration of these drugs. Closely monitor when CAMZYOS is used with concomitant CYP3A4, CYP2C9, or CYP2C19 substrates unless otherwise recommended in the Prescribing Information.

Certain Combined Hormonal Contraceptives (CHCs): Progestin and ethinyl estradiol are CYP3A4 substrates. Concomitant use of CAMZYOS may decrease exposures of certain progestins, which may lead to contraceptive failure. CHCs containing a combination of ethinyl estradiol and norethindrone may be used with CAMZYOS, but if other CHCs are used, advise patients to add nonhormonal contraception (such as condoms) or use an alternative contraceptive method that is not affected by CYP450 enzyme induction (eg intrauterine system) during concomitant use and for 4 months after the last dose of CAMZYOS.

Drugs That Reduce Cardiac Contractility

Expect additive negative inotropic effects of CAMZYOS and other drugs that reduce cardiac contractility. Avoid concomitant use of CAMZYOS in patients on disopyramide, ranolazine, verapamil with a beta blocker, or diltiazem with a beta blocker as these medications and combinations increase the risk of left ventricular systolic dysfunction and heart failure symptoms and clinical experience is limited.

If concomitant therapy with a negative inotrope is initiated, or if the dose of a negative inotrope is increased, monitor LVEF closely until stable doses and clinical response have been achieved.

SPECIFIC POPULATIONS

Pregnancy

CAMZYOS may cause fetal harm when administered to a pregnant female. Advise pregnant females about the potential risk to the fetus with maternal exposure to CAMZYOS during pregnancy. There is a pregnancy safety study for CAMZYOS. If CAMZYOS is administered during pregnancy, or if a patient becomes pregnant while receiving CAMZYOS or within 4 months after the last dose of CAMZYOS, healthcare providers should report CAMZYOS exposure by contacting Bristol Myers Squibb at 1-800-721-5072 or www.bms.com.

Lactation

The presence of CAMZYOS in human or animal milk, the drug’s effects on the breastfed infant, or the effects on milk production are unknown. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for CAMZYOS and any potential adverse effects on the breastfed child from CAMZYOS or from the underlying maternal condition.

Females and Males of Reproductive Potential

Confirm absence of pregnancy in females of reproductive potential prior to initiation of CAMZYOS. Advise females of reproductive potential to use effective contraception during treatment with CAMZYOS and for 4 months after the last dose. CHCs containing a combination of ethinyl estradiol and norethindrone may be used with CAMZYOS. However, CAMZYOS may reduce the effectiveness of certain other CHCs. If these CHCs are used, advise patients to add nonhormonal contraception (such as condoms) or use an alternative contraceptive method during concomitant use and for 4 months after the last dose of CAMZYOS.

INDICATION

CAMZYOS® (mavacamten) is indicated for the treatment of adults with symptomatic New York Heart Association (NYHA) Class II-III obstructive hypertrophic cardiomyopathy (HCM) to improve functional capacity and symptoms.

Please see US  Full Prescribing Information, including  Boxed WARNING.

3500-US-2500487 07/25

Bristol Myers SquibbTM Logo

Legal Notice     Privacy Policy     Your Privacy Choices

© 2025 MyoKardia, Inc., a Bristol Myers Squibb company. 
CAMZYOS® and the CAMZYOS and MyCAMZYOS Logos are trademarks of MyoKardia, Inc.

3500-US-2400621   04/25

This site is intended for U.S. Healthcare Professionals only.